EUCTR2017-000214-27-PL进行中（未招募）1 期
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of the efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Patients with Moderate-to-Severe Plaque Psoriasis
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, 18 to 80 years of age, inclusive;
- •2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement
- •=10%, as judged by the Investigator;
- •3. PASI score =12 (Appendix 3);
- •4. Static PGA =3 (Appendix 2);
- •5. Candidate for systemic treatment or phototherapy for psoriasis;
- •6. Duration of psoriasis of at least 6 months;
- •7. Females of childbearing potential must have a negative serum pregnancy test at screening;
- •8. Female subjects of childbearing potential must use highly effective contraception throughout the course of the trial and for 3 months after. Highly effective methods include hormonal contraception (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants; each method must be used with a barrier method, preferably male condom), intrauterine device or system, tubal ligation, partner vasectomy, or dual (male plus female) barrier methods (each barrier method must be used with a hormonal method).
- •Female subjects who use a hormonally based method must agree to use it in conjunction with a barrier method. Female partners of male study subjects should consider using one of the above methods of contraception as well. Post-menopausal status is defined as menopause for at least 1 year prior to the Screening Visit and must be confirmed by an elevated serum FSH level.
- •9. Male subjects must refrain from sperm donation during treatment and until at least 90 days after the end of study drug dosing. Male subjects with fertile or pregnant partners must agree to use condoms throughout the course of the trial and for 3 months after.
- •10. Ability to complete the study in compliance with the protocol; and
- •11. Ability to understand and provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 375
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •1. Psoriasis limited to erythrodermic, guttate, palmar, plantar, or
- •generalized pustular psoriasis in the absence of plaque psoriasis;
- •2. Prior treatment with apremilast within 4 weeks prior to the Baseline
- •visit, or contraindication to apremilast;
- •3. Treatment with systemic retinoids, corticosteroids, tofacitinib, or
- •immunosuppressive agents (e.g., methotrexate, cyclosporine) within 4
- •weeks of the Baseline visit;
- •4. Treatment with a biological agent (etanercept, adalimumab,
- •efalizumab, infliximab, ustekinumab, alefacept, secukinumab, or others, including investigational agents) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit;
- •5. Treatment with high potency topical dermatological corticosteroids
- •(Class I-III in US, Class III-IV in Europe), Vitamin D analogs, keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit;
- •6. Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period;
- •7. Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period, unless dose has been stable for 3 months prior to the Screening visit and will remain stable throughout the trial;
- •8. Serum creatinine level greater than 1.25 times the laboratory's upper limit of normal at Screening;
- •9. Liver aminotransferase levels greater than 1.5 times the laboratory's upper limit of normal at Screening;
- •10. QTcF interval on Screening Visit ECG or on average of triplicate
- •Baseline Visit ECGs >450 milliseconds (msec) for males or > 470 msec
- •for females (except when QT prolongation is associated with right or left bundle branch block, in which case enrollment is allowed);
- •11. A condition which increases proarrhythmic risk, including
- •hypokalemia, hypomagnesemia, or congenital Long QT Syndrome;
- •12. Heart disease which is, in the Investigator's judgment, clinically
- •13. Ongoing or planned use of a concomitant medication that is on the CredibleMedsTM list of drugs known to cause Torsades des Pointes (Appendix 7);
- •14. Active gastrointestinal disease which could interfere with the
- •absorption of oral medication;
- •15. Pregnancy, planned pregnancy, lactation, or inadequate
- •contraception as judged by the Investigator;
- •16. Active drug or alcohol dependence;
- •17. History of depression or suicidal ideation within the past year;
- •18. Concomitant use of strong cytochrome P450 inducers, e.g., rifampin, phenobarbital, phenytoin, carbamazepine;
- •19. Previous participation in a piclidenoson (CF101) clinical trial, defined as having received at least one dose of study medication;
- •20. Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
- •21. Participation in another investigational drug or vaccine trial
- •concurrently or within 30 days prior to the Screening visit.
研究者
相似试验
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVRespiratory Syncytial VirusMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002023-11-HUJanssen-Cilag International NV737
进行中（未招募）
1 期
Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone.Type 1 Diabetes MellitusEUCTR2014-005153-39-LTexicon Pharmaceuticals, Inc.750
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVEUCTR2020-002023-11-SEJanssen-Cilag International NV737
进行中（未招募）
1 期
A Study of the Effects of AMG 334 to Prevent Migraine HeadachesEUCTR2014-004464-38-NLAmgen Inc852
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)Immunoglobulin A Nephropathy (IgAN)EUCTR2020-003084-26-CZChinook Therapeutics U.S., Inc.320